COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). Th ...

COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-fund ...

COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) ...

Financial Performance - For the three months ended June 30, 2023, total operating expenses were $5,677,000, a decrease of 9.3% compared to $6,259,000 for the same period in 2022[5]. - The net loss for the period was $5,683,000, compared to a net loss of $4,768,000 for the same period in 2022, reflecting an increase of 19.2%[5]. - The total comprehensive loss for the six months ended June 30, 2023, was $11,891,000, compared to $12,764,000 for the same period in 2022, showing a slight improvement of 6.9%[5]. - Research and development expenses for the six months ended June 30, 2023, were $6,788,000, down 24% from $8,916,000 in the same period of 2022[5]. - The company reported finance income of $47,000 for the three months ended June 30, 2023, a significant decrease from $1,539,000 in the same period of 2022[5]. Cash and Assets - Cash and cash equivalents decreased to $7,118,000 as of June 30, 2023, down from $13,184,000 at the beginning of the year, representing a decline of 46%[8]. - Total assets decreased to $16,754,000 as of June 30, 2023, from $22,025,000 as of December 31, 2022, a reduction of 24%[8]. - The accumulated deficit increased to $84,257,000 as of June 30, 2023, compared to $72,659,000 at the end of 2022, indicating a rise of 15.9%[8]. Financing and Capital Needs - The company plans to finance cash needs through equity offerings or other capital sources, requiring additional financing by December 2023[18]. - The company raised $5,973,000 from the issuance of shares and exercise of warrants during the six months ended June 30, 2023[12]. - The company entered into a Purchase Agreement to sell up to $40 million of its ordinary shares over a 36-month period, with no sales made as of June 30, 2023[24]. - The company has a financing agreement of up to $20 million with Global Growth Holding Limited as of July 31, 2023[26]. - The company’s current cash position and forecasted cash requirements indicate a need for additional financing to continue operations and product development[17]. Legal Proceedings - As of June 30, 2023, the Company and SSI have agreed to pause ongoing court proceedings and begin out-of-court negotiations[71]. - The Company believes ongoing legal proceedings will not materially impact future financial results[71]. - The Company believes it has strong defenses against SSI's claim regarding the Invention[70]. - The Company does not expect a material impact on its rights to use the Invention for developing and commercializing EVX-01[70]. - The Company intends to vigorously defend against SSI's claim, which it believes is without merit[70]. Going Concern - The company has significant doubt about its ability to continue as a going concern for at least one year from the balance sheet date due to ongoing losses and funding needs[19]. Shareholder Information - The carrying amount of the warrant liability decreased from $573,000 at January 1, 2023, to $402,000 at June 30, 2023, due to remeasurement[46]. - As of June 30, 2023, the number of warrants as a percentage of outstanding ordinary shares was 8.6%, down from 11.0% in 2022[47]. - The company granted 10,000 warrants to an employee on March 15, 2023, which vest over 36 months[50]. - The company sold 3,160,208 ordinary shares represented by ADSs from January 1, 2023, to June 30, 2023, at a volume weighted average price of $1.84 per ADS, generating approximately $6.0 million in gross proceeds[64]. - The company issued 428,572 ordinary shares as a commitment fee of $1.2 million for Lincoln Park's commitment under the Purchase Agreement[24].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...

Exhibit1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 2. Kapitalforhold 2. Capital 2.2 Kapitalejers navn og adresse indføres i selskabets ejerbog. Ejerbogen føres af Computershare A/S (CVR-nr. 27088899). 2.3 Ingen aktie har særlige rettigheder og ingen kapitalejer er pligtig at lade sine aktier indløse. 2.3 No share carries any special rights and no shareholder is obliged to let his shares be redeemed. 2.5 Bestyrelsen er i periode ...

Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After todayÂ's presentation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of ...

Financial Data and Key Metrics Changes - In Q1 2022, cash and cash equivalents were US$31.4 million, a decrease from US$32.2 million as of December 31, 2021 [13] - Research and development expenses increased to US$4.8 million in Q1 2022 from US$3.9 million in Q1 2021, primarily due to higher employee-related costs [14] - General and administrative expenses rose to US$1.6 million in Q1 2022 from US$1.3 million in Q1 2021, attributed to increased external costs [14] - The net loss for Q1 2022 was US$5.8 million, or US$0.25 loss per share, compared to a net loss of US$4.1 million, or US$0.23 loss per share in Q1 2021 [15] Business Line Data and Key Metrics Changes - The company is advancing its lead cancer therapy, EVX-01, towards a Phase 2b clinical trial in combination with Merck's KEYTRUDA for metastatic melanoma [6][7] - Recruitment for the Phase 1/2a clinical trial of EVX-02 has been completed, and it is moving into a dedicated Phase 2b clinical trial for patients with resectable melanoma [8] Market Data and Key Metrics Changes - The company is actively discussing potential partnerships with pharmaceutical and biotech companies, aiming for solid progress in 2022 [7] Company Strategy and Development Direction - The company aims to improve the treatment landscape for melanoma and other cancers using its existing pipeline of cancer therapies [6] - Plans to select a second bacterial product candidate from the EDEN platform and the first viral candidate from the RAVEN platform in the second half of 2022 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving significant progress in partnerships and clinical trials throughout 2022 [7] - The company is focused on validating its AI models to identify unique drug targets, which may enhance clinical success rates [10][22] Other Important Information - The company received regulatory clearance to initiate the Phase 2b trial of EVX-01 in January 2022, with the first patient visit expected in the first half of 2022 [8] - The manufacturing process for personalized medicine has been established, allowing for production timelines of 10 to 12 weeks for EVX-02 [20] Q&A Session Summary Question: Timing for an update on Phase 2a EVX-01 durability of response - Management expects to have data available within the next half to nine months, as they are continuously following up on patients [17] Question: Number of sites for EVX-01 Phase 2b study and enrollment pace - Initial recruitment will start in Australia with multiple sites, targeting to open 10 to 12 global sites [18] Question: Update on EVX-03 in light of EVX-02 advancement - Management is considering speeding up EVX-03 based on data from EVX-02, with ongoing data collection [19] Question: Production timeline for EVX-02 and update on EVX-03 - EVX-02 can be manufactured in 10 to 12 weeks, and this capability is crucial for future trials [20] Question: Data expectations from the ImmunoID NeXT Platform - The company is working to validate its AI system for selecting patients who will respond to immune therapy, with data expected to materialize during the year [23] Question: Timeline for data readout on EVX-02 - Management expects to share data in 2023, focusing on safety and immunological profiling [25] Question: Regulatory submissions for EVX-01 in the EU and U.S. - The process is moving according to plan, with expectations to start in EMA first, followed by FDA [26] Question: Legal proceedings with SSI around CAF09 - Management stated there is no material risk to the conduct of studies, as they already have a license for CAF09 [28]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...